COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma (COPLA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04357106|
Recruitment Status : Unknown
Verified April 2020 by Guillermo J. RUIZ-ARGÜELLES, Centro de Hematología y Medicina Interna.
Recruitment status was: Recruiting
First Posted : April 22, 2020
Last Update Posted : April 22, 2020
|Condition or disease||Intervention/treatment||Phase|
|COVID-19||Biological: Convalescent plasma||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma|
|Actual Study Start Date :||April 13, 2020|
|Estimated Primary Completion Date :||July 2020|
|Estimated Study Completion Date :||August 2020|
Experimental: Convalescent Plasma
200 ml of convalescent plasma, single dose.
Biological: Convalescent plasma
Convalescent plasma obtained by aphaeresis from recovered patients.
- Lung injury [ Time Frame: 7 days ]PaO2/FiO2 relation
- Overall survival [ Time Frame: 15-30 days ]Patients survival after therapy
- Adverse reactions to plasma [ Time Frame: 7 days ]Determine the incidence of side effects from plasma administration
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04357106
|Contact: Juan Carlos Olivares-Gazca, MD, MPHfirstname.lastname@example.org|
|Contact: José Manuel Priesca-Marin, MDemail@example.com|
|Centro de Hematología y Medicina Interna||Recruiting|
|Puebla, Mexico, 72530|
|Contact: Juan Carlos Olivares-Gazca, MD,MPH 2222438100 firstname.lastname@example.org|
|Principal Investigator: Guillermo J Ruiz-Arguelles, MD, FRCP, MACP, DSc|